MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- DR. REDDYS LAB
DR. REDDYS LAB Share Price 
(REDY)
Here is the latest stock price and chart of Dr. Reddys. For more details, see the Dr. Reddys company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Dec 14, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)2,591.60 | Open (Rs) 2,624.90 | High (Rs) 2,624.90 | Low (Rs) 2,569.00 |
| % Change-0.17 | Volume 24,052 | Value (Rs) 62,209,587 | 52-Week H/L 2,745.00 / 1,888.00 |
| Live NSE Quotes | Dec 14, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)2,591.70 | Open (Rs) 2,595.00 | High (Rs) 2,609.60 | Low (Rs) 2,568.00 |
| % Change-0.20 | Volume 586,360 | Value (Rs) 1,516,469,942 | 52-Week H/L 2,749.95 / 1,887.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 93.52 | P/E Ratio (x) 27.71 | Market Cap (Rs m) 429,454.04 | P/BV (x) 3.42 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
DR. REDDYS LAB Share Price Today:
DR. REDDYS LAB last traded price was down 0.2% to Rs 2,591.6 on the BSE. On the NSE, DR. REDDYS LAB last traded price was down 0.2% to Rs 2,591.7. The total volume of shares traded was 0.6 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.8%. And the benchmark S&P BSE SENSEX was at 35,962.9 (up 0.1%).
Over the last 30 days, the DR. REDDYS LAB share price is up 5.9%. And over the last one year, DR. REDDYS LAB share price is up 12.0%.
|
| |
Today's Market
From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)
The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.
Related Views On News
DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)
Jul 27, 2018 | Updated on Jul 27, 2018For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)
Nov 13, 2017Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.
Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)
Aug 8, 2017Profits plunge due to higher raw material costs.
More Views on NewsMost Popular
4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)
Dec 3, 2018Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.
It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)
Dec 6, 2018My latest StockSelect recommendation ticks all the boxes of a great safe stock.
Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)
Dec 5, 2018Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.
Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)
Dec 3, 2018After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...
DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)
Dec 5, 2018PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.
MoreTRACK DR. REDDYS LAB
- Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. REDDYS LAB
DR. REDDYS LAB - ADCOCK INGRAM COMPARISON
COMPARE DR. REDDYS LAB WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.